Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 15 de 15
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Cell Transplant ; 30: 963689721993769, 2021.
Article de Anglais | MEDLINE | ID: mdl-33840257

RÉSUMÉ

Until July 29th, the number of confirmed coronavirus (COVID-19) cases worldwide has risen to over 16 million, within which 655 k deaths. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) emerges as the 11th global pandemic disease, showing the highest infectivity and lowest infection fatality rate. In this review, we compare the immunopathology among SARS-CoV, Middle East respiratory syndrome coronavirus, and SARS-CoV2. SARS-CoV2 is similar to SARS-CoV; it can cause lymphocytopenia and a rising granulocyte count. Here we point out the human body and concentrated society make for an excellent incubator for virus evolution. Most research energies put into developing the SARS-CoV2 vaccine are trying to block virus infection. Sixty-five percent of severe patients die with multiple organ failure, inflammation, and cytokine storm, which indicates that the patient's immune system maintains functionality. Finding a way to trigger the specific T cell subset and plasmablast in our body is the best shot to get away with SARS-CoV2.


Sujet(s)
COVID-19/immunologie , SARS-CoV-2/immunologie , Animaux , COVID-19/anatomopathologie , Coronavirus/immunologie , Infections à coronavirus/immunologie , Infections à coronavirus/anatomopathologie , Syndrome de libération de cytokines/immunologie , Syndrome de libération de cytokines/anatomopathologie , Humains , Inflammation/immunologie , Inflammation/anatomopathologie , Virus du SRAS/immunologie , Syndrome respiratoire aigu sévère/immunologie , Syndrome respiratoire aigu sévère/anatomopathologie
2.
Cell Transplant ; 30: 963689721996217, 2021.
Article de Anglais | MEDLINE | ID: mdl-33845643

RÉSUMÉ

COVID-19 has spread worldwide, including the United States, United Kingdom, and Italy, along with its site of origin in China, since 2020. The virus was first found in the Wuhan seafood market at the end of 2019, with a controversial source. The clinical symptoms of COVID-19 include fever, cough, and respiratory tract inflammation, with some severe patients developing an acute and chronic lung injury, such as acute respiratory distress syndrome (ARDS) and pulmonary fibrosis (PF). It has already claimed approximately 300 thousand human lives and the number is still on the rise; the only way to prevent the infection is to be safe till vaccines and reliable treatments develop. In previous studies, the use of mesenchymal stem cells (MSCs) in clinical trials had been proven to be effective in immune modulation and tissue repair promotion; however, their efficacy in treating COVID-19 remains underestimated. Here, we report the findings from past experiences of SARS and MSCs, and how SARS could also induce PF. Such studies may help to understand the rationale for the recent cell-based therapies for COVID-19.


Sujet(s)
COVID-19/complications , Transplantation de cellules souches mésenchymateuses , Fibrose pulmonaire/étiologie , Animaux , COVID-19/sang , COVID-19/anatomopathologie , COVID-19/thérapie , Coronavirus/isolement et purification , Humains , Transplantation de cellules souches mésenchymateuses/méthodes , Fibrose pulmonaire/sang , Fibrose pulmonaire/anatomopathologie , Fibrose pulmonaire/thérapie , Système rénine-angiotensine , SARS-CoV-2/isolement et purification , Syndrome respiratoire aigu sévère/sang , Syndrome respiratoire aigu sévère/complications , Syndrome respiratoire aigu sévère/anatomopathologie , Syndrome respiratoire aigu sévère/thérapie , Facteur de croissance transformant bêta/sang
3.
Cell Transplant ; 29: 963689720927394, 2020.
Article de Anglais | MEDLINE | ID: mdl-32854518

RÉSUMÉ

Mammalian fat comprises white and brown adipose tissue (WAT and BAT, respectively). WAT stores energy, whereas BAT is used for thermogenesis. In recent years, the incidence of obesity and its associated disorders have increased tremendously. Considering the thermogenic capacity and decreased levels of BAT with increasing age, BAT can be used as a suitable therapeutic target for the treatment of obesity and diabetes. In several studies, using positron emission tomography and computed tomography images, adult humans have been shown to have functional BAT in interscapular fat. Results of these basic research studies on BAT have shed light on the new components of transcriptional regulation and the role of hormones in stimulating BAT growth and differentiation. In this review article, we have summarized the thermogenic regulators identified in the past decades by focusing on peroxisome proliferator-activated receptor gamma/uncoupling protein 1 activators, branched-chain amino acids, fatty acids (lipokine), and adenosine monophosphate-activated protein kinase mediators. We have also presented the progress of a few ongoing clinical trials aimed at the treatment of obesity and its associated metabolic disorders. The main purpose of this review was to provide a comprehensive introduction to the latest knowledge of the representative thermogenic regulators for the treatment of obesity. The fat combustion capacity of BAT may have great potential and can be considered as a suitable target for the therapeutic application of drugs from bench-to-bed treatment of obesity and the associated diseases.


Sujet(s)
Tissu adipeux brun/effets des médicaments et des substances chimiques , Obésité/traitement médicamenteux , Obésité/thérapie , Bibliothèques de petites molécules/pharmacologie , Thermogenèse/effets des médicaments et des substances chimiques , Animaux , Humains , Métabolisme lipidique/effets des médicaments et des substances chimiques , Obésité/métabolisme , Bibliothèques de petites molécules/usage thérapeutique
4.
Int J Mol Sci ; 21(12)2020 Jun 21.
Article de Anglais | MEDLINE | ID: mdl-32575820

RÉSUMÉ

Although butylidenephthalide (BP) is an efficient anticancer drug, its poor bioavailability renders it ineffective for treating drug-resistant brain tumors. However, this problem is overcome through the use of noninvasive delivery systems, including intranasal administration. Herein, the bioavailability, drug stability, and encapsulation efficiency (EE, up to 95%) of BP were improved by using cyclodextrin-encapsulated BP in liposomal formulations (CDD1). The physical properties and EE of the CDD1 system were investigated via dynamic light scattering, transmission electron microscopy, UV-Vis spectroscopy, and nuclear magnetic resonance spectroscopy. The cytotoxicity was examined via MTT assay, and the cellular uptake was observed using fluorescence microscopy. The CDD1 system persisted for over 8 h in tumor cells, which was a considerable improvement in the retention of the BP-containing cyclodextrin or the BP-containing liposomes, thereby indicating a higher BP content in CDD1. Nanoscale CDD1 formulations were administered intranasally to nude mice that had been intracranially implanted with temozolomide-resistant glioblastoma multiforme cells, resulting in increased median survival time. Liquid chromatography-mass spectrometry revealed that drug biodistribution via intranasal delivery increased the accumulation of BP 10-fold compared to oral delivery methods. Therefore, BP/cyclodextrin/liposomal formulations have potential clinical applications for treating drug-resistant brain tumors.


Sujet(s)
Antinéoplasiques/pharmacocinétique , Encéphale/métabolisme , Systèmes de délivrance de médicaments , Anhydrides phtaliques/pharmacocinétique , Animaux , Antinéoplasiques/administration et posologie , Biodisponibilité , Encéphale/effets des médicaments et des substances chimiques , Tumeurs du cerveau/traitement médicamenteux , Tumeurs du cerveau/métabolisme , Cyclodextrines/composition chimique , Glioblastome/traitement médicamenteux , Glioblastome/métabolisme , Liposomes/composition chimique , Mâle , Souris de lignée BALB C , Souris nude , Anhydrides phtaliques/administration et posologie , Distribution tissulaire
5.
Cell Transplant ; 29: 963689720907565, 2020.
Article de Anglais | MEDLINE | ID: mdl-32233795

RÉSUMÉ

Stem cell transplantation is a fast-developing technique, which includes stem cell isolation, purification, and storage, and it is in high demand in the industry. In addition, advanced applications of stem cell transplantation, including differentiation, gene delivery, and reprogramming, are presently being studied in clinical trials. In contrast to somatic cells, stem cells are self-renewing and have the ability to differentiate; however, the molecular mechanisms remain unclear. SOX2 (sex-determining region Y [SRY]-box 2) is one of the well-known reprogramming factors, and it has been recognized as an oncogene associated with cancer induction. The exclusion of SOX2 in reprogramming methodologies has been used as an alternative cancer treatment approach. However, the manner by which SOX2 induces oncogenic effects remains unclear, with most studies demonstrating its regulation of the cell cycle and no insight into the maintenance of cellular stemness. For controlling certain critical pathways, including Shh and Wnt pathways, SOX2 is considered irreplaceable and is required for the normal functioning of stem cells, particularly neural stem cells. In this report, we discussed the functions of SOX2 in both stem and cancer cells, as well as how this powerful regulator can be used to control cell fate.


Sujet(s)
Facteurs de transcription SOX-B1/métabolisme , Transplantation de cellules souches/méthodes , Animaux , Différenciation cellulaire/génétique , Différenciation cellulaire/physiologie , Prolifération cellulaire/génétique , Prolifération cellulaire/physiologie , Reprogrammation cellulaire/génétique , Reprogrammation cellulaire/physiologie , Humains , Cellules souches neurales/cytologie , Cellules souches neurales/métabolisme , Facteurs de transcription SOX-B1/génétique
6.
Molecules ; 24(22)2019 Nov 19.
Article de Anglais | MEDLINE | ID: mdl-31752262

RÉSUMÉ

Fibrosis is a type of chronic organ failure, resulting in the excessive secretion of extracellular matrix (ECM). ECM protects wound tissue from infection and additional injury, and is gradually degraded during wound healing. For some unknown reasons, myofibroblasts (the cells that secrete ECM) do not undergo apoptosis; this is associated with the continuous secretion of ECM and reduced ECM degradation even during de novo tissue formation. Thus, matrix metalloproteinases (MMPs) are considered to be a potential target of fibrosis treatment because they are the main groups of ECM-degrading enzymes. However, MMPs participate not only in ECM degradation but also in the development of various biological processes that show the potential to treat diseases such as stroke, cardiovascular diseases, and arthritis. Therefore, treatment involving the targeting of MMPs might impede typical functions. Here, we evaluated the links between these MMP functions and possible detrimental effects of fibrosis treatment, and also considered possible approaches for further applications.


Sujet(s)
Fibrose/étiologie , Fibrose/métabolisme , Matrix metalloproteinases/métabolisme , Matrix metalloproteinases/pharmacologie , Animaux , Prédisposition aux maladies , Activation enzymatique , Matrice extracellulaire/métabolisme , Fibrose/traitement médicamenteux , Régulation de l'expression des gènes , Humains , Immunomodulation , Matrix metalloproteinases/génétique , Matrix metalloproteinases/usage thérapeutique , Myofibroblastes/métabolisme , Néovascularisation pathologique , Spécificité d'organe/génétique , Protéolyse , Cicatrisation de plaie
7.
Int J Nanomedicine ; 14: 3601-3613, 2019.
Article de Anglais | MEDLINE | ID: mdl-31190814

RÉSUMÉ

Introduction: Kolliphor® EL (K-EL) is among the most useful surfactants in the preparation of emulsions. However, it is associated with low hydrophobic drug loading in the resulting emulsified formulation. Methods: In this study, a formulation for intranasal administration of butylidenephthalide (Bdph), a candidate drug against glioblastoma (GBM), was prepared. Physical characteristics of the formulation such as particle size, zeta potential, conductivity, and viscosity were assessed, as well as its cytotoxicity and permeability, in order to optimize the formulation and improve its drug loading capacity. Results: The optimized formulation involved the integration of polyethylene glycol 400 (PEG 400) in K-EL to encapsulate Bdph dissolved in dimethyl sulfoxide (DMSO), and it exhibited higher drug loading capacity and drug solubility in water than the old formulation, which did not contain PEG 400. Incorporation of PEG 400 as a co-surfactant increased Bdph loading capacity to up to 50% (v/v), even in formulations using Kolliphor® HS 15 (K-HS15) as a surfactant, which is less compatible with Bdph than K-EL. The optimized Bdph formulation presented 5- and 2.5-fold higher permeability and cytotoxicity, respectively, in human GBM than stock Bdph. This could be attributed to the high drug loading capacity and the high polarity index due to DMSO, which increases the compatibility between the drug and the cell. Rats bearing a brain glioma treated with 160 mg/kg intranasal emulsified Bdph had a mean survival of 37 days, which is the same survival time achieved by treatment with 320 mg/kg stock Bdph. This implies that the optimized emulsified formulation required only half the Bdph dose to achieve an efficacy similar to that of stock Bdph in the treatment of animals with malignant brain tumor.


Sujet(s)
Tumeurs du cerveau/traitement médicamenteux , Systèmes de délivrance de médicaments , Émulsions/composition chimique , Nanoparticules/composition chimique , Muqueuse nasale/physiologie , Polyéthylène glycols/composition chimique , Animaux , Tumeurs du cerveau/anatomopathologie , Mort cellulaire/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Gliome/traitement médicamenteux , Gliome/anatomopathologie , Humains , Concentration inhibitrice 50 , Mâle , Nanoparticules/ultrastructure , Taille de particule , Perméabilité , Anhydrides phtaliques/composition chimique , Rats de lignée F344 , Solubilité , Tensioactifs/composition chimique , Analyse de survie , Charge tumorale , Viscosité
8.
Pharmacol Res ; 139: 50-61, 2019 01.
Article de Anglais | MEDLINE | ID: mdl-30385365

RÉSUMÉ

Annually, 48,000 people die from pancreatic ductal adenocarcinoma (PDAC), ranking it the fourth among cancer-related deaths in the United States. Currently, anti-cancer drugs are not effective against PDAC, and only extends survival by 3 months. Aberrant DNA methylation has been shown to play an important role during carcinogenesis in PDAC, with approximately 80% of tumor overexpressing the DNA methyltransferase 1 (DNMT1) protein. In the present study, we used DNMTs as a screening platform to find a new DNMT inhibitor, n-butylidenephthalide (n-BP), which is identified from a Chinese herbal drug. n-BP could inhibit DNMT1 expression in both dose-dependent and time-dependent manner. It also displays an effect in suppressing growth of PDAC cells and inducing cell cycle arrest at G0/G1 phase leading apoptosis. Growth suppression can be restored by the overexpression of DNMT1 in PDAC cells. Furthermore, we found n-BP-mediated DNMT1 suppression influenced the protein stability rather than changing the RNA expression. Through microarray studies, we found that the patched domain contained 4 (PTCHD4) is the potential downstream gene of DNMT1. Following silencing of PTCHD4 expression by siRNA, n-BP decreased tumor growth inhibition. Finally, in vivo, two animal models were used to evaluate the efficacy and survival after n-BP treatment by interstitial control release polymer delivery. The results show that n-BP could effectively inhibit PDAC tumor volume growth and extend animal survival. In summary, n-BP may inhibit the growth of human PDAC cells though reducing DNMT1 and increasing the expression of PTCHD4 both in vitro and in vivo.


Sujet(s)
Carcinome du canal pancréatique/traitement médicamenteux , DNA modification methylases/antagonistes et inhibiteurs , Protéines Hedgehog/antagonistes et inhibiteurs , Tumeurs du pancréas/traitement médicamenteux , Anhydrides phtaliques/pharmacologie , Anhydrides phtaliques/usage thérapeutique , Animaux , Carcinome du canal pancréatique/génétique , Carcinome du canal pancréatique/métabolisme , Lignée cellulaire tumorale , DNA modification methylases/génétique , DNA modification methylases/métabolisme , Épigenèse génétique , Humains , Mâle , Souris de lignée BALB C , Souris nude , Tumeurs du pancréas/génétique , Tumeurs du pancréas/métabolisme , Polymères/pharmacologie , Polymères/usage thérapeutique , Petit ARN interférent/génétique , Protéines de répression/génétique
9.
Int J Mol Sci ; 19(10)2018 Oct 04.
Article de Anglais | MEDLINE | ID: mdl-30287739

RÉSUMÉ

Pulmonary fibrosis is a fatal respiratory disease that gradually leads to dyspnea, mainly accompanied by excessive collagen production in the fibroblast and myofibroblast through mechanisms such as abnormal alveolar epithelial cells remodeling and stimulation of the extracellular matrix (ECM). Our results show that a small molecule, butylidenephthalide (BP), reduces type I collagen (COL1) expression in Transforming Growth Factor beta (TGF-ß)-induced lung fibroblast without altering downstream pathways of TGF-ß, such as Smad phosphorylation. Treatment of BP also reduces the expression of transcription factor Sex Determining Region Y-box 2 (SOX2), and the ectopic expression of SOX2 overcomes the inhibitory actions of BP on COL1 expression. We also found that serial deletion of the SOX2 binding site on 3'COL1 promoter results in a marked reduction in luciferase activity. Moreover, chromatin immunoprecipitation, which was found on the SOX2 binding site of the COL1 promoter, decreases in BP-treated cells. In an in vivo study using a bleomycin-induced pulmonary fibrosis C57BL/6 mice model, mice treated with BP displayed reduced lung fibrosis and collagen deposition, recovering in their pulmonary ventilation function. The reduction of SOX2 expression in BP-treated lung tissues is consistent with our findings in the fibroblast. This is the first report that reveals a non-canonical regulation of COL1 promoter via SOX2 binding, and contributes to the amelioration of pulmonary fibrosis by BP treatment.


Sujet(s)
Anhydrides phtaliques/pharmacologie , Fibrose pulmonaire/métabolisme , Animaux , Lignée cellulaire , Collagène de type I/métabolisme , Fibroblastes/effets des médicaments et des substances chimiques , Fibroblastes/métabolisme , Humains , Mâle , Souris , Souris de lignée C57BL , Anhydrides phtaliques/usage thérapeutique , Régions promotrices (génétique) , Fibrose pulmonaire/traitement médicamenteux , Facteurs de transcription SOX-B1/génétique , Facteurs de transcription SOX-B1/métabolisme
10.
Cell Transplant ; 27(11): 1581-1587, 2018 Nov.
Article de Anglais | MEDLINE | ID: mdl-29991279

RÉSUMÉ

Although the clinical application of new drugs has been shown to be effective in slowing disease progression and improving the quality of life in patients with pulmonary fibrosis, the damaged lung tissue does not recover with these drugs. Thus, there is an urgent need to establish regenerative therapy, such as stem cell therapy or tissue engineering. Moreover, the clinical application of mesenchymal stem cell (MSC) therapy has been shown to be safe in humans with idiopathic pulmonary fibrosis (IPF). It seems that a combination of MSC transplantation and pharmaceutical therapy might have additional benefits; however, the experimental design for its efficacy is still lacking. In this review, we provide an overview of the mechanisms that were identified when IPF was treated with MSC transplantation or new drugs. To maximize the therapeutic effect, we suggest that MSC transplantation is combined with drug application for synergistic effects. This review provides clinicians and scientists with the most efficient medical options, in the hope that this will spur on future research and lead to an eventual cure for this disease.

11.
Molecules ; 23(2)2018 Jan 28.
Article de Anglais | MEDLINE | ID: mdl-29382106

RÉSUMÉ

Traditional Chinese medicine has been practiced for centuries in East Asia. Herbs are used to maintain health and cure disease. Certain Chinese herbs are known to protect and improve the brain, memory, and nervous system. To apply ancient knowledge to modern science, some major natural therapeutic compounds in herbs were extracted and evaluated in recent decades. Emerging studies have shown that herbal compounds have neuroprotective effects or can ameliorate neurodegenerative diseases. To understand the mechanisms of herbal compounds that protect against neurodegenerative diseases, we summarize studies that discovered neuroprotection by herbal compounds and compound-related mechanisms in neurodegenerative disease models. Those compounds discussed herein show neuroprotection through different mechanisms, such as cytokine regulation, autophagy, endoplasmic reticulum (ER) stress, glucose metabolism, and synaptic function. The interleukin (IL)-1ß and tumor necrosis factor (TNF)-α signaling pathways are inhibited by some compounds, thus attenuating the inflammatory response and protecting neurons from cell death. As to autophagy regulation, herbal compounds show opposite regulatory effects in different neurodegenerative models. Herbal compounds that inhibit ER stress prevent neuronal death in neurodegenerative diseases. Moreover, there are compounds that protect against neuronal death by affecting glucose metabolism and synaptic function. Since the progression of neurodegenerative diseases is complicated, and compound-related mechanisms for neuroprotection differ, therapeutic strategies may need to involve multiple compounds and consider the type and stage of neurodegenerative diseases.


Sujet(s)
Médicaments issus de plantes chinoises/usage thérapeutique , Stress du réticulum endoplasmique/effets des médicaments et des substances chimiques , Maladies neurodégénératives , Neurones/métabolisme , Neuroprotecteurs/usage thérapeutique , Transduction du signal/effets des médicaments et des substances chimiques , Animaux , Mort cellulaire/effets des médicaments et des substances chimiques , Cytokines/métabolisme , Humains , Maladies neurodégénératives/traitement médicamenteux , Maladies neurodégénératives/métabolisme , Maladies neurodégénératives/anatomopathologie , Neurones/anatomopathologie
12.
Int J Mol Sci ; 18(2)2017 Feb 10.
Article de Anglais | MEDLINE | ID: mdl-28208648

RÉSUMÉ

Glioblastoma (GBM) is one of the most common and aggressive types of brain tumor. Due to its highly recurrent rate and poor prognosis, the overall survival time with this type of tumor is only 20-21 months. Recent knowledge suggests that its recurrence is in part due to the presence of cancer stem cells (CSCs), which display radioresistant, chemoresistant, self-renewal and tumorigenic potential. Enhancers of Zeste 2 (EZH2) and AXL receptor tyrosine kinase (AXL) are both highly expressed in GBM. Additionally, they are an essential regulator involved in CSCs maintenance, migration, invasion, epithelial-to-mesenchymal transition (EMT), stemness, metastasis and patient survival. In this study, we used a small molecule, n-butylidenephthalide (BP), to assess the anti-GBM stem-like cells potential, and then tried to find out the associated genes involved with regulation in migration and invasion. We demonstrated that BP reduced the expression of AXL and stemness related genes in a dose-dependent manner. The migratory and invasive capabilities of GBM stem-like cells could be reduced by AXL/EZH2. Finally, in the overexpression of AXL, EZH2 and Sox2 by transfection in GBM stem-like cells, we found that AXL/EZH2/TGF-ꞵ1, but not Sox2, might be a key regulator in tumor invasion, migration and EMT. These results might help in the development of a new anticancer compound and can be a target for treating GBM.


Sujet(s)
Protéine-2 homologue de l'activateur de Zeste/génétique , Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Glioblastome/génétique , Cellules souches tumorales/effets des médicaments et des substances chimiques , Cellules souches tumorales/métabolisme , Anhydrides phtaliques/pharmacologie , Protéines proto-oncogènes/génétique , Récepteurs à activité tyrosine kinase/génétique , Marqueurs biologiques , Tumeurs du cerveau/génétique , Tumeurs du cerveau/métabolisme , Tumeurs du cerveau/anatomopathologie , Cycle cellulaire/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Mouvement cellulaire/effets des médicaments et des substances chimiques , Mouvement cellulaire/génétique , Prolifération cellulaire/effets des médicaments et des substances chimiques , Auto-renouvellement cellulaire/effets des médicaments et des substances chimiques , Auto-renouvellement cellulaire/génétique , Transition épithélio-mésenchymateuse/effets des médicaments et des substances chimiques , Transition épithélio-mésenchymateuse/génétique , Glioblastome/métabolisme , Glioblastome/anatomopathologie , Humains , Modèles biologiques , Phénotype , Axl Receptor Tyrosine Kinase
13.
Front Pharmacol ; 7: 112, 2016.
Article de Anglais | MEDLINE | ID: mdl-27199755

RÉSUMÉ

The treatment of liver fibrosis has clinical limitations because of its multiple etiologies, such as epithelial-mesenchymal transition (EMT) promotion, cell regeneration and remodeling dysfunction, inflammatory cell activation, and scar tissue deposition. These factors might be considered as a new target for the fibrotic microenvironment, leading to increased fibrogenesis and liver fibrosis. Here, we investigate a small molecule named butylidenephthalide (BP) and its multiple effects on liver fibrosis treatment. Thioacetamide was used in vivo to induce chronic liver fibrosis. BP was administered orally in rats for a period of 2 and 4 weeks, which resulted in a significantly reduced fibrosis score (p < 0.05) and (p < 0.001), respectively. The inflammatory reaction of macrophage infiltration were reduced in the administration of BP, which led to the decrease in the transaminase levels. Moreover, we also found liver functions recovering (due to the increased serum albumin and reduced prothrombin time) where liver cells regenerated, which can be seen in the increase of Ki-67 on Oval cell. In addition, the fibrotic scar was also reduced, along with the expression of matrix metalloprotease by hepatic stellate cell. Furthermore, regarding the mechanism/study of EMT reduced by BP, the knockdown of BMP-7, which could reduce α-SMA expression, was mediated by the regulation of TGF-ß, which implies its major role on EMT. Finally, in the in vivo study, BP treatment of liver fibrosis was reduced by Bmp7 knockdown in zebrafish, suggesting that BP leads to the reduction of liver fibrosis, which also depends on BMP-7 induction. These results suggest that BP had multiple targets for treating liver fibrosis in the following ways: reduction of EMT, decreasing inflammatory reaction, and liver cell proliferation. This multiple targets approach provided a new mechanism to treat liver injury and fibrosis.

14.
Fitoterapia ; 99: 227-35, 2014 Dec.
Article de Anglais | MEDLINE | ID: mdl-25173462

RÉSUMÉ

Taiwanin A (α,ß-bis(piperonylidene)-γ-butyrolactone) is extracted from Taiwania cryptomerioides. Taiwanin A is extracted from tree bark and exhibits antitumor activity in breast, liver, and lung cancer cell lines. The objective of this study was to demonstrate the cytotoxicity of Taiwanin A against tumor cells by increasing the expression of non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1). NAG-1 has been reported to exhibit antitumor and proapoptotic activities, suggesting potential use in cancer therapy. Inhibiting NAG-1 mRNA expression in A549 reduced the cytotoxicity caused by Taiwanin A. Furthermore, the c-Jun-N-terminal kinase/Ste20-related protein proline/alanine-rich kinase (JNK/SPAK) pathway played a key role in the influence of NAG-1 on cell viability, whereas the addition of the JNK pathway inhibitor SP600125 resulted in an inhibitory effect on NAG-1 and recovery of Taiwanin-A-treated cells. A xenograft tumor model demonstrated that Taiwanin A dose-dependently significantly decreases tumor-mediated growth in nude mice by increasing the NAG-1 expression accompanying tumor apoptosis. These data supported the hypothesis that Taiwanin A inhibits lung carcinoma growth by increasing NAG-1 expression through the JNK pathway both in vivo and in vitro. This result can contribute to a compound design for increasing cytotoxicity activity in the future.


Sujet(s)
Antinéoplasiques d'origine végétale/pharmacologie , Furanes/pharmacologie , Facteur-15 de croissance et de différenciation/métabolisme , Lignanes/pharmacologie , Tumeurs du poumon/métabolisme , Animaux , Anthracènes/pharmacologie , Apoptose , Lignée cellulaire tumorale , Humains , JNK Mitogen-Activated Protein Kinases/métabolisme , Système de signalisation des MAP kinases/effets des médicaments et des substances chimiques , Souris de lignée BALB C , Souris nude , Protein-Serine-Threonine Kinases/métabolisme , Tests d'activité antitumorale sur modèle de xénogreffe
15.
Cell Transplant ; 23(4-5): 399-406, 2014.
Article de Anglais | MEDLINE | ID: mdl-24816441

RÉSUMÉ

Human mesenchymal stem cells (hMSCs) are currently available for a range of applications and benefits and have become a good material for regenerative medicine, tissue engineering, and disease therapy. Before ex vivo expansion, isolation and characterization of primary hMSCs from peripheral tissues are key steps for obtaining adequate materials for clinical application. The proportion of peripheral stem cells is very low in surrounding tissues and organs; thus the recovery ratio will be a limiting factor. In this review, we summarized current common methods used to isolate peripheral stem cells, as well as the new insights revealed to improve the quantity of stem cells and their stemness. These strategies offer alternative ways to acquire hMSCs in a convenient and/or effective manner, which is important for clinical treatments. Improved isolation and mass amplification of the hMSCs while ensuring their stemness and quantity will be an important step for clinical use. Enlarged suitable hMSCs are more clinically applicable for therapeutic transplants and may help people live longer and better.


Sujet(s)
Séparation cellulaire/méthodes , Cellules souches mésenchymateuses/cytologie , Tissu adipeux/cytologie , Cellules de la moelle osseuse/cytologie , Séparation cellulaire/instrumentation , Humains , Cellules souches mésenchymateuses/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE